GenSight appoints new COO
This article was originally published in Scrip
Executive Summary
Paris, France-based GenSight Biologics, which develops gene-based therapies to preserve or restore vision in people with degenerative retinal and inherited ophthalmologic diseases, has named Dr Jean-Philippe Combal chief operating officer. Dr Combal will lead the company's operational activities and the development of its products. Prior to joining GenSight, he was leading development of early stage dermatological products – up to Phase IIb – at Galderma International.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.